A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

PURPOSE: Docetaxel has activity against androgen-independent prostate cancer and preclinical studies have shown that taxane-based chemotherapy can enhance antitumor response of vaccines. The primary objective of this study was to determine if concurrent docetaxel (with dexamethasone) had any effect...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2006-02, Vol.12 (4), p.1260-1269
Hauptverfasser:	ARLEN, Philip M, GULLEY, James L, STEINBERG, Seth M, JONES, Elizabeth, CHEN, Clara, MARTE, Jennifer, SCHLOM, Jeffrey, DAHUT, William, PARKER, Catherine, SKARUPA, Lisa, PAZDUR, Mary, PANICALI, Dennis, BEETHAM, Patricia, TSANG, Kwong Y, GROSENBACH, Douglas W, FELDMAN, Jarett
Format:	Artikel
Sprache:	eng
Schlagworte:	Acid Phosphatase - blood Aged Aged, 80 and over Androgens - physiology Antigens - blood Antigens, Neoplasm Antigens, Surface - blood Antineoplastic agents Antineoplastic Agents, Phytogenic - therapeutic use Biological and medical sciences Cancer Vaccines - immunology Cancer Vaccines - therapeutic use Combined Modality Therapy Cross-Over Studies Disease-Free Survival Fowlpox virus Glutamate Carboxypeptidase II - blood Glycoproteins - blood Gynecology. Andrology. Obstetrics Humans Leukocytes, Mononuclear - drug effects Leukocytes, Mononuclear - metabolism Male Male genital diseases Medical sciences Middle Aged Mucin-1 Mucins - blood Neoplasm Metastasis Nephrology. Urinary tract diseases Pharmacology. Drug treatments Prostate-Specific Antigen - blood Prostatic Neoplasms - drug therapy Prostatic Neoplasms - immunology Prostatic Neoplasms - physiopathology Taxoids - therapeutic use Time Factors Treatment Outcome Tumors Tumors of the urinary system Urinary tract. Prostate gland Vaccination - methods Vaccinia virus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!